The Drug Safety Research Unit (DSRU) established the international group that consists of pharma giants such as Pfizer, Roche, BMS, Takeda, Lilly, Gilead, Alexion and Celgene to explore better ways of identifying adverse side effects from licensed medicines.
The independent research unit, dubbed the International Working Group on Signal Detection and Management in Pharmacovigilance, convened an initial meeting of 40 international members from around the world to represent each pharmaceutical company, along with regulatory authorities and academic institutions.
The gathering – which took place in London, UK – explored key topics, such as how big data and Artificial Intelligence can aid signal detection in monitoring the safety of medicines in clinical use.
Peter De Veene, executive director, global drug safety at Alexion Pharmaceuticals, said: “Coming together as a multi-expert group provides the opportunity to find solutions to make the process of pharmacovigilance more efficient and to ensure that 21st century technology can be applied to the different types of new data sources that have emerged over the last few years.
« In the end, this will ultimately serve to better protect patients and ensure the detection of adverse events happens earlier in the process than ever before.”…